The University of Arizona
Map Home
Loading...
Adjust height of sidebar
KMap

Grant

A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alt-100 in Patients With Moderate to Severe Acute Respiratory Distress Syndrome (ARDS)

Sponsored by Novotech Clinical Research USA, LLC

Active
$498.4K Funding
9 People
External

Related Topics

Abstract

PUERTA is a Phase 2a, randomized, double-blind, placebo-controlled study in adults with moderate to severe ARDS consequent to sepsis, septic shock, trauma, and/or bacterial or viral pneumonia who have been hospitalized. The safety and tolerability, PK, preliminary efficacy and PD of a single infusion of ALT-100 will be assessed.

People